Recent studies suggest blood levels of phosphorylated tau (p-tau) isoforms can detect both the tau and amyloid pathologies that define Alzheimer disease (AD).1 More research is needed to replicate these results in large, diverse cohorts and quantify a p-tau blood test’s ability to prognosticate the onset of dementia. Nevertheless, we anticipate that the ability to receive diagnostic and prognostic information with the ease of a blood test will revolutionize AD research and care. We also anticipate that it will be the basis of a profitable direct-to-consumer (DTC) test, one that highlights considerable ethical and social challenges of DTC testing and AD.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Largent EA, Wexler A, Karlawish J. The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests. JAMA Neurol. Published online January 04, 2021. doi:10.1001/jamaneurol.2020.4835
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: